All Venous thromboembolism articles
-
eLearning moduleManagement of venous thromboembolism in primary care
This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100953 | February 2022 -
SIGN guideline
SIGN venous thromboembolism in COVID-19 guideline
A short summary of recommendations on preventing and managing COVID-19-related venous thromboembolism in the community
-
News
EMA confirms risk of new blood disorder with Janssen COVID-19 vaccine
The Agency’s Pharmacovigilance Risk Assessment Committee recommends raising awareness of a possible link between the vaccine and VTE
-
News
Blood clot risks ‘lower with COVID vaccines than from infection’
A study has found the risk of haematological and vascular adverse events following a first dose of two COVID vaccines was significantly lower than from infection with SARS-CoV-2
-
News
NICE publishes new COVID-19 guideline on reducing VTE
NICE has published a new guideline on pharmacological venous thromboembolism prophylaxis for patients being treated for COVID-19 pneumonia, which includes patients receiving treatment in hospital or in a community setting
-
NICE guideline
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
This useful summary covers diagnosis and initial management, outpatient treatment for low-risk pulmonary embolism, anticoagulation treatment for suspected or confirmed deep vein thrombosis or pulmonary embolism, and information and support for people having anticoagulation treatment
